Aurobindo Pharma Limited (AUROPHARMA.BO)
INR 1096.8
(0.16%)
INR 1096.8
(0.16%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 39.23 Billion INR | -34.84% |
| 2022 | 101.79 Billion INR | 10.04% |
| 2021 | 92.51 Billion INR | -2.32% |
| 2020 | 94.7 Billion INR | 11.63% |
| 2019 | 84.83 Billion INR | 28.71% |
| 2018 | 65.91 Billion INR | 15.34% |
| 2017 | 57.14 Billion INR | 19.59% |
| 2016 | 47.78 Billion INR | 15.02% |
| 2015 | 41.54 Billion INR | 6.68% |
| 2014 | 38.94 Billion INR | 67.63% |
| 2013 | 23.23 Billion INR | 21.78% |
| 2012 | 19.07 Billion INR | 34.76% |
| 2011 | 14.15 Billion INR | 19.97% |
| 2010 | 11.79 Billion INR | 20.87% |
| 2009 | 9.76 Billion INR | -29.68% |
| 2008 | 13.88 Billion INR | 87.49% |
| 2007 | 7.4 Billion INR | 32.08% |
| 2006 | 5.6 Billion INR | 22.17% |
| 2005 | 4.58 Billion INR | 77.42% |
| 2004 | 2.58 Billion INR | -36.17% |
| 2003 | 4.05 Billion INR | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 18.02 Billion INR | -0.17% |
| 2023 Q3 | 29.42 Billion INR | 0.49% |
| 2023 Q1 | 28.11 Billion INR | 30.1% |
| 2023 Q2 | 29.28 Billion INR | 4.17% |
| 2023 FY | 66.33 Billion INR | -34.84% |
| 2023 Q4 | 18.05 Billion INR | -38.63% |
| 2022 Q3 | 28.47 Billion INR | 10.93% |
| 2022 Q2 | 25.66 Billion INR | -1.46% |
| 2022 Q1 | 26.04 Billion INR | 41.75% |
| 2022 FY | 101.79 Billion INR | 10.04% |
| 2022 Q4 | 21.6 Billion INR | -24.12% |
| 2021 Q1 | 23.95 Billion INR | 43.56% |
| 2021 Q4 | 18.37 Billion INR | -27.31% |
| 2021 Q3 | 25.27 Billion INR | 1.45% |
| 2021 FY | 92.51 Billion INR | -2.32% |
| 2021 Q2 | 24.91 Billion INR | 4.0% |
| 2020 FY | 94.7 Billion INR | 11.63% |
| 2020 Q3 | 26.88 Billion INR | 0.08% |
| 2020 Q2 | 26.86 Billion INR | 10.75% |
| 2020 Q1 | 24.26 Billion INR | 32.65% |
| 2020 Q4 | 16.68 Billion INR | -37.93% |
| 2019 Q2 | 22.25 Billion INR | 3.39% |
| 2019 Q4 | 18.28 Billion INR | -19.67% |
| 2019 FY | 84.83 Billion INR | 28.71% |
| 2019 Q1 | 21.52 Billion INR | 101.71% |
| 2019 Q3 | 22.76 Billion INR | 2.28% |
| 2018 Q2 | 18.46 Billion INR | 7.44% |
| 2018 Q4 | 10.67 Billion INR | -42.68% |
| 2018 FY | 65.91 Billion INR | 15.34% |
| 2018 Q1 | 17.18 Billion INR | -0.8% |
| 2018 Q3 | 18.62 Billion INR | 0.86% |
| 2017 Q3 | 16.31 Billion INR | -3.07% |
| 2017 FY | 57.14 Billion INR | 19.59% |
| 2017 Q4 | 17.32 Billion INR | 6.2% |
| 2017 Q2 | 16.82 Billion INR | 14.43% |
| 2017 Q1 | 14.7 Billion INR | -3.11% |
| 2016 Q4 | 15.17 Billion INR | 7.42% |
| 2016 Q1 | 13.46 Billion INR | -1.33% |
| 2016 FY | 47.78 Billion INR | 15.02% |
| 2016 Q2 | 13.71 Billion INR | 1.84% |
| 2016 Q3 | 14.12 Billion INR | 3.0% |
| 2015 FY | 41.54 Billion INR | 6.68% |
| 2015 Q4 | 13.65 Billion INR | 10.41% |
| 2015 Q3 | 12.36 Billion INR | 5.99% |
| 2015 Q2 | 11.66 Billion INR | 1.4% |
| 2015 Q1 | 11.5 Billion INR | 47.65% |
| 2014 Q3 | 11.34 Billion INR | 6.12% |
| 2014 Q4 | 7.79 Billion INR | -31.32% |
| 2014 FY | 38.94 Billion INR | 67.63% |
| 2014 Q1 | 9.63 Billion INR | 124.23% |
| 2014 Q2 | 10.69 Billion INR | 11.01% |
| 2013 Q3 | 6.75 Billion INR | 6.65% |
| 2013 FY | 23.23 Billion INR | 21.78% |
| 2013 Q2 | 6.32 Billion INR | 7.55% |
| 2013 Q1 | 5.88 Billion INR | 112.79% |
| 2013 Q4 | 4.29 Billion INR | -36.37% |
| 2012 Q3 | 5.89 Billion INR | 6.52% |
| 2012 Q2 | 5.53 Billion INR | 13.86% |
| 2012 Q4 | 2.76 Billion INR | -53.09% |
| 2012 FY | 19.07 Billion INR | 34.76% |
| 2012 Q1 | 4.86 Billion INR | 165.39% |
| 2011 Q3 | 4.43 Billion INR | 0.0% |
| 2011 FY | 14.15 Billion INR | 19.97% |
| 2011 Q4 | 1.83 Billion INR | -58.66% |
| 2010 FY | 11.79 Billion INR | 20.87% |
| 2009 FY | 9.76 Billion INR | -29.68% |
| 2008 FY | 13.88 Billion INR | 87.49% |
| 2007 FY | 7.4 Billion INR | 32.08% |
| 2006 FY | 5.6 Billion INR | 22.17% |
| 2005 FY | 4.58 Billion INR | 77.42% |
| 2004 FY | 2.58 Billion INR | -36.17% |
| 2003 FY | 4.05 Billion INR | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 15.86 Billion INR | -147.233% |
| Glenmark Life Sciences Limited | 11.64 Billion INR | -237.052% |
| Granules India Limited | 7.18 Billion INR | -446.271% |
| Indoco Remedies Limited | 4.74 Billion INR | -726.218% |
| Achyut Healthcare Limited | 1.6 Million INR | -2438383.53% |
| Ajanta Pharma Limited | 30.46 Billion INR | -28.798% |
| Alkem Laboratories Limited | 32.83 Billion INR | -19.492% |
| Alpa Laboratories Limited | 156.14 Million INR | -25027.092% |
| Brooks Laboratories Limited | 51.18 Million INR | -76561.196% |
| AstraZeneca Pharma India Limited | 2.6 Billion INR | -1408.814% |
| Bajaj HealthCare Limited | 985.34 Million INR | -3881.874% |
| Bliss GVS Pharma Limited | 1.41 Billion INR | -2664.557% |
| Dr. Reddy's Laboratories Limited | 95.87 Billion INR | 59.078% |
| Eris Lifesciences Limited | 4.94 Billion INR | -693.762% |
| FDC Limited | 5.34 Billion INR | -633.57% |
| Glenmark Pharmaceuticals Limited | 67.56 Billion INR | 41.929% |
| Gufic Biosciences Limited | 1.07 Billion INR | -3540.605% |
| Ind-Swift Laboratories Limited | 2.12 Billion INR | -1747.072% |
| Ipca Laboratories Limited | 13.91 Billion INR | -181.965% |
| Jagsonpal Pharmaceuticals Limited | 773.41 Million INR | -4973.014% |
| Krebs Biochemicals & Industries Limited | 46.15 Million INR | -84905.633% |
| Lasa Supergenerics Limited | 291.17 Million INR | -13374.829% |
| Laurus Labs Limited | 3.01 Billion INR | -1203.149% |
| Lupin Limited | 95.67 Billion INR | 58.99% |
| Mankind Pharma Limited | 23.15 Billion INR | -69.462% |
| Medicamen Biotech Limited | 335.16 Million INR | -11606.164% |
| Medico Remedies Limited | 161.84 Million INR | -24142.604% |
| Megasoft Limited | 49.52 Million INR | -79118.222% |
| NATCO Pharma Limited | 10.05 Billion INR | -290.089% |
| Piramal Pharma Limited | 19.91 Billion INR | -97.023% |
| RPG Life Sciences Limited | 1.63 Billion INR | -2298.973% |
| Sigachi Industries Limited | 579.88 Million INR | -6666.008% |
| Sun Pharmaceutical Industries Limited | 154.18 Billion INR | 74.553% |
| Suven Pharmaceuticals Limited | 1.4 Billion INR | -2696.942% |
| Syncom Formulations (India) Limited | 942.39 Million INR | -4063.332% |
| Unichem Laboratories Limited | 6.72 Billion INR | -483.348% |
| Wanbury Limited | 1.16 Billion INR | -3279.644% |
| Windlas Biotech Limited | 1 Billion INR | -3798.143% |
| ZIM Laboratories Limited | 1.01 Billion INR | -3772.947% |
| Zydus Lifesciences Limited | 43.17 Billion INR | 9.123% |
| Sun Pharma Advanced Research Company Limited | 3.07 Billion INR | -1175.195% |
| Divi's Laboratories Limited | 14.17 Billion INR | -176.889% |
| Hester Biosciences Limited | 908.84 Million INR | -4217.064% |
| Procter & Gamble Health Limited | 2.99 Billion INR | -1209.848% |
| Amrutanjan Health Care Limited | 1.09 Billion INR | -3470.121% |
| Bal Pharma Limited | 389.89 Million INR | -9963.146% |
| Strides Pharma Science Limited | 9.16 Billion INR | -328.224% |
| Venus Remedies Limited | 1.91 Billion INR | -1947.463% |
| Aarti Pharmalabs Limited | 3.07 Billion INR | -1176.19% |
| Nectar Lifesciences Limited | 625.55 Million INR | -6172.113% |
| Shilpa Medicare Limited | 2.18 Billion INR | -1699.294% |
| Aarti Drugs Limited | 1.16 Billion INR | -3260.677% |
| IOL Chemicals and Pharmaceuticals Limited | 1.09 Billion INR | -3470.732% |
| Suven Life Sciences Limited | 109.75 Million INR | -35649.613% |
| Ind-Swift Limited | 946.56 Million INR | -4045.0% |
| Valiant Laboratories Limited | 36.28 Million INR | -108018.714% |
| J. B. Chemicals & Pharmaceuticals Limited | 8.41 Billion INR | -366.138% |
| Solara Active Pharma Sciences Limited | 4.57 Billion INR | -756.72% |
| Themis Medicare Limited | 782.85 Million INR | -4911.809% |
| Hikal Limited | 2.48 Billion INR | -1478.03% |
| Torrent Pharmaceuticals Limited | 21.42 Billion INR | -83.153% |
| Sequent Scientific Limited | 2.9 Billion INR | -1252.094% |
| Novartis India Limited | 470.1 Million INR | -8246.139% |
| Wockhardt Limited | 6.4 Billion INR | -513.05% |
| Jubilant Pharmova Limited | 14.45 Billion INR | -171.449% |
| Biofil Chemicals and Pharmaceuticals Limited | 16.2 Million INR | -241947.678% |
| Neuland Laboratories Limited | 2.92 Billion INR | -1239.201% |
| Morepen Laboratories Limited | 1.98 Billion INR | -1874.148% |
| Kilitch Drugs (India) Limited | 412.42 Million INR | -9413.247% |
| Mangalam Drugs & Organics Limited | 676.14 Million INR | -5702.762% |